RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Accounts receivable, net

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndAccounts receivable, net (Million USD)YoY (%)
Dec 31, 20246,212+9.61%
Dec 31, 20235,667+6.35%
Dec 31, 20225,329-11.73%
Dec 31, 20216,037+94.01%
Dec 31, 20203,112+48.17%
Dec 31, 20192,100+21.83%
Dec 31, 20181,724+12.03%
Dec 31, 20171,539+14.54%
Dec 31, 20161,343+16.56%
Dec 31, 20151,152+55.87%
Dec 31, 2014739-6.06%
Dec 31, 2013787+32.68%
Dec 31, 2012593+1999.55%
Dec 31, 201128+109.15%
Dec 31, 201014

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)